Autoimmune hemolytic anemia

Researchers are testing an experimental intravenous drug called F182112 in adults with autoimmune hemolytic anemia that has returned or resisted multiple treatments. The trial enrolls about 12 people and gives the drug at three increasing dose levels to check safety, tolerability…

This phase 1 trial tests a one-time infusion of AZD0120, a CAR-T cell therapy that targets CD19 and BCMA, in people with relapsed or refractory immune thrombocytopenia (ITP) or warm autoimmune hemolytic anemia (wAIHA). Participants receive a short course of bendamustine before th…

This early-phase study tests whether combining mesenchymal stem cells (MSCs) with specially engineered immune cells (CAR-T cells) is safe and can help control autoimmune diseases. About 30 adults with established autoimmune conditions will receive the treatment and be monitored f…

This study tests whether specially engineered immune cells, called CAR-T cells, can safely treat autoimmune diseases. The cells are designed to target and suppress B cells, which play a key role in many autoimmune conditions. The trial involves 30 adults and focuses on safety and…

This early-stage trial tests clonal fetal mesenchymal stem cells (cfMSCs) in 100 people with severe immune-related disorders or tissue damage. The goal is to see if the cells are safe and can reduce symptoms. Participants have no other treatment options left.

This trial is testing an investigational drug called velinotamig in adults with immune thrombocytopenia (ITP) or warm autoimmune hemolytic anemia (wAIHA) that has relapsed or not responded to standard treatments. Velinotamig is an engineered bispecific antibody designed to target…

This phase 2 trial tests a personalized CAR T cell therapy called zolacabtagene autoleucel in 52 adults with chronic immune thrombocytopenia (ITP) or autoimmune hemolytic anemia (AIHA). The treatment uses the patient's own immune cells, modified to target and destroy faulty B cel…

This early-phase trial tests a new therapy called META 10-19 for people with autoimmune hemolytic anemia (AIHA) that has not responded to standard treatments. AIHA is a condition where the immune system mistakenly destroys red blood cells, causing anemia. META 10-19 uses a patien…

This study tests whether removing a specific type of immune cell (naive T cells) from a donor's stem cell graft can prevent graft-versus-host disease (GVHD), a serious complication where donor cells attack the recipient's body. The trial enrolls people with non-malignant blood di…

This early study tests an experimental drug called STR-P005 in people with autoimmune diseases that have come back or not improved with standard treatments. The drug is given through an IV in multiple doses. The main goal is to check safety and see how the body handles the drug. …

This early study tests a new drug called STR-P005 in 18 people with autoimmune diseases that have not responded to standard treatments. The main goal is to check safety and find the best dose. Participants receive the drug by infusion in different schedules, and researchers will …

This early-phase study tests whether combining two drugs (Zuberitamab and Orelabrutinib) can help people with immune thrombocytopenia (ITP) or autoimmune hemolytic anemia (AIHA) that hasn't responded to other treatments. The drugs work together to calm the immune system and stop …

This early-phase study tests a new treatment called IASO206 for people whose autoimmune hemolytic anemia (AIHA) has not responded to standard therapies. AIHA is a condition where the immune system mistakenly destroys red blood cells, causing fatigue and other symptoms. The study …

This study tests whether adding sirolimus to standard steroid treatment helps people with newly diagnosed mild autoimmune hemolytic anemia (AIHA) achieve lasting remission. About 216 adults will be randomly assigned to get either steroids alone or steroids plus sirolimus for 6 mo…

This early-stage trial tests a new cell therapy called YTS109 for people with autoimmune hemolytic anemia that hasn't improved after at least three prior treatments. The therapy uses specially engineered immune cells to target and destroy the faulty cells causing the anemia. The …

This early-phase study tests a new mRNA therapy that targets CD19, a protein on immune cells, to treat autoimmune diseases like lupus and immune anemia. The treatment uses lipid nanoparticles to deliver mRNA that helps the body clear harmful B cells. About 47 participants aged 14…

This early-stage trial tests a new treatment called CD19/BCMA CAR-T cell therapy for people with a severe type of autoimmune anemia that hasn't responded to standard treatments. The therapy uses a patient's own immune cells, modified in a lab to attack the faulty immune cells cau…

This early-phase trial tests a new cell therapy called YTS109 in 13 adults with autoimmune hemolytic anemia that has not responded to at least three prior treatments. The therapy uses specially engineered immune cells to target and control the disease. The main goals are to check…

This phase 2 trial is testing a drug called enatumab in 3 adults with relapsed or refractory warm antibody autoimmune hemolytic anemia (wAIHA), a condition where the immune system destroys red blood cells. Current treatments often stop working or cause relapses. Enatumab is given…

This early-stage trial tests a new CAR-T cell therapy called inaticabtagene autoleucel for people with autoimmune hemolytic anemia (AIHA) that hasn't improved after at least three prior treatments. The study will enroll 12 adults and primarily check for safety and the right dose.…

This phase 2 trial tests linprixel, a daily pill, in 22 adults with relapsed or refractory autoimmune hemolytic anemia (AIHA). The study aims to see if the drug can improve red blood cell counts after 12 weeks. Participants start at 40mg daily, with possible dose increases if nee…

This study tests whether blood samples collected at home using small capillary devices, like finger pricks, give the same results as traditional blood draws from a vein. Researchers will compare both methods in about 1,000 people with chronic conditions such as kidney disease, au…

Anemia often goes unnoticed because diagnosis requires a blood draw. This study tests whether a wrist-worn smartwatch can identify people likely to have anemia by tracking blood flow, heart rate, oxygen, and movement. About 400 adults, with and without anemia, will wear the watch…

This study tests whether a non-invasive device that uses light to measure hemoglobin through the skin can accurately detect anemia. Researchers will compare its readings with standard blood tests in 150 adults in Jakarta. If the device proves reliable, it could offer a quick, pai…

This trial investigates whether annual re-screening for tuberculosis infection using a blood test (IGRA) can prevent active TB in people with autoimmune rheumatic diseases who are taking biologic or immunosuppressive medications. Participants who initially test negative for TB ar…

This study tests whether a single dose of amoxicillin before a simple tooth extraction can prevent infections in people with autoimmune rheumatic diseases who are on immune-suppressing medications. Researchers will compare infection rates between those who get the antibiotic and …

This study will test a new way to offer vaccines to vulnerable patients—those with chronic diseases or weakened immune systems—during hospital visits. Researchers will see if offering, prescribing, and giving vaccines in the hospital increases how many people get vaccinated. The …